Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Get this delivered to your inbox, and more info about our products and services.
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does, too.
Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
CNBC's Jim Cramer made the list and shared it with Club members during Friday's December Monthly Meeting.
Danaher shares fell on the news that it was acquiring medtech player Masimo.
This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround.
